MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 534784 | Name: Methylnaltrexone

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Methylnaltrexone is a narcotic antagonists.

Chemical Structure

Methylnaltrexone
Methylnaltrexone
CAS#83387-25-1

Theoretical Analysis

MedKoo Cat#: 534784

Name: Methylnaltrexone

CAS#: 83387-25-1

Chemical Formula: C21H26NO4+

Exact Mass: 356.1856

Molecular Weight: 356.44

Elemental Analysis: C, 70.76; H, 7.35; N, 3.93; O, 17.95

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Methylnaltrexone
IUPAC/Chemical Name
17-(Cyclopropylmethyl)-4,5alpha-epoxy-3,14-dihydroxy-17-methyl-6-oxomorphinanium
InChi Key
JVLBPIPGETUEET-SQGFOMTPSA-O
InChi Code
InChI=1S/C21H25NO4/c1-22(11-12-2-3-12)9-8-20-17-13-4-5-14(23)18(17)26-19(20)15(24)6-7-21(20,25)16(22)10-13/h4-5,12,16,19,25H,2-3,6-11H2,1H3/p+1/t16-,19-,20+,21-,22?/m1/s1
SMILES Code
O=C1[C@@H]2[C@]34C5=C(O2)C(O)=CC=C5C[C@@H]([N+](C)(CC6CC6)CC4)[C@]3(O)CC1
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 356.44 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Mehta N, O'Connell K, Giambrone GP, Baqai A, Diwan S. Efficacy of methylnaltrexone for the treatment of opiod-induced constipation: a meta- analysis and systematic review. Postgrad Med. 2016;128(3):282-9. doi: 10.1080/00325481.2016.1149017. Epub 2016 Feb 23. PMID: 26839023. 2: Mozaffari S, Nikfar S, Abdollahi M. Methylnaltrexone bromide for the treatment of opioid-induced constipation. Expert Opin Pharmacother. 2018 Jul;19(10):1127-1135. doi: 10.1080/14656566.2018.1491549. Epub 2018 Jul 6. PMID: 29979903. 3: Uritsky TJ. Methylnaltrexone: Peripherally Acting µ-Opioid Receptor Antagonist. J Adv Pract Oncol. 2019 Jan-Feb;10(1):62-67. Epub 2019 Jan 1. PMID: 31308989; PMCID: PMC6605701. 4: Garnock-Jones KP, McKeage K. Methylnaltrexone. Drugs. 2010 May 7;70(7):919-28. doi: 10.2165/11204520-000000000-00000. PMID: 20426500. 5: Nelson KK, Schattner MA, Mendelsohn RB. Methylnaltrexone is safe in cancer patients with peritoneal carcinomatosis. Sci Rep. 2019 Jul 3;9(1):9625. doi: 10.1038/s41598-019-44864-2. PMID: 31270339; PMCID: PMC6610621. 6: López J, Fernández SN, Santiago MJ, Urbano J, González R, Fernández- Llamazares C, López-Herce J. Methylnaltrexone for the Treatment of Constipation in Critically Ill Children. J Clin Gastroenterol. 2016 Apr;50(4):351-2. doi: 10.1097/MCG.0000000000000483. PMID: 26950234. 7: Hendrikx JJ, Beijnen JH, Schellens JH. Methylnaltrexone. Oncologist. 2009 Jul;14(7):679-82. doi: 10.1634/theoncologist.2009-0049. Epub 2009 Jul 15. PMID: 19605844. 8: Rauck RL, Slatkin NE, Stambler N, Israel RJ. Safety of oral methylnaltrexone for opioid-induced constipation in patients with chronic noncancer pain. J Pain Res. 2018 Dec 24;12:139-150. doi: 10.2147/JPR.S170086. PMID: 30613162; PMCID: PMC6307492. 9: Webster LR, Israel RJ. Oral methylnaltrexone does not negatively impact analgesia in patients with opioid-induced constipation and chronic noncancer pain. J Pain Res. 2018 Aug 13;11:1503-1510. doi: 10.2147/JPR.S160488. PMID: 30147355; PMCID: PMC6095122. 10: Moss J. Identifying and Treating Opioid Side Effects: The Development of Methylnaltrexone. Anesthesiology. 2019 Jan;130(1):142-148. doi: 10.1097/ALN.0000000000002428. PMID: 30277930. 11: Schoergenhofer C, Jilma B. Methylnaltrexone to Reduce the Inhibitory Effects of Opioids on Drug Absorption. JACC Cardiovasc Interv. 2019 Aug 26;12(16):1550-1552. doi: 10.1016/j.jcin.2019.06.029. Epub 2019 Jul 31. PMID: 31377266. 12: Tahir M, Singh A, Amjad W. Methylnaltrexone for Neostigmine-Resistant Ogilvie Syndrome. Am J Ther. 2018 Nov/Dec;25(6):e727-e728. doi: 10.1097/MJT.0000000000000743. PMID: 29509554. 13: Methylnaltrexone: MNTX. Drugs R D. 2006;7(6):374-8. doi: 10.2165/00126839-200607060-00006. PMID: 17073520. 14: Franchi F, Rollini F, Park Y, Hu J, Kureti M, Rivas Rios J, Faz G, Yaranov D, Been L, Pineda AM, Suryadevara S, Soffer D, Zenni MM, Bass TA, Angiolillo DJ. Effects of Methylnaltrexone on Ticagrelor-Induced Antiplatelet Effects in Coronary Artery Disease Patients Treated With Morphine. JACC Cardiovasc Interv. 2019 Aug 26;12(16):1538-1549. doi: 10.1016/j.jcin.2019.05.028. Epub 2019 Jul 31. PMID: 31377269. 15: Merchan C, Altshuler D, Papadopoulos J. Methylnaltrexone Versus Naloxone for Opioid-Induced Constipation in the Medical Intensive Care Unit. Ann Pharmacother. 2017 Mar;51(3):203-208. doi: 10.1177/1060028016677310. Epub 2016 Nov 13. PMID: 28168885. 16: Movik E, Ringerike T, Linnestad KK, Hofmann B, Harboe I, Klemp M. Methylnaltrexone for Opioid-Induced Constipation in Cancer Treatment [Internet]. Oslo, Norway: Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH); 2009 Oct. Report from Norwegian Knowledge Centre for the Health Services (NOKC) No. 23-2009. PMID: 29320106. 17: Webster LR, Israel RJ. Oral methylnaltrexone is efficacious and well tolerated for the treatment of opioid-induced constipation in patients with chronic noncancer pain receiving concomitant methadone. J Pain Res. 2018 Oct 23;11:2509-2516. doi: 10.2147/JPR.S160625. PMID: 30425563; PMCID: PMC6205130. 18: Janku F, Johnson LK, Karp DD, Atkins JT, Singleton PA, Moss J. Treatment with methylnaltrexone is associated with increased survival in patients with advanced cancer. Ann Oncol. 2016 Nov;27(11):2032-2038. doi: 10.1093/annonc/mdw317. Epub 2016 Aug 29. Erratum in: Ann Oncol. 2018 Apr 1;29(4):1076. PMID: 27573565; PMCID: PMC6267944. 19: Rotshteyn Y, Boyd TA, Yuan CS. Methylnaltrexone bromide: research update of pharmacokinetics following parenteral administration. Expert Opin Drug Metab Toxicol. 2011 Feb;7(2):227-35. doi: 10.1517/17425255.2011.549824. Epub 2011 Jan 11. PMID: 21222554. 20: Candy B, Jones L, Goodman ML, Drake R, Tookman A. Laxatives or methylnaltrexone for the management of constipation in palliative care patients. Cochrane Database Syst Rev. 2011 Jan 19;(1):CD003448. doi: 10.1002/14651858.CD003448.pub3. Update in: Cochrane Database Syst Rev. 2015;5:CD003448. PMID: 21249653.